CA2534664A1 - Modafinil compositions - Google Patents

Modafinil compositions Download PDF

Info

Publication number
CA2534664A1
CA2534664A1 CA002534664A CA2534664A CA2534664A1 CA 2534664 A1 CA2534664 A1 CA 2534664A1 CA 002534664 A CA002534664 A CA 002534664A CA 2534664 A CA2534664 A CA 2534664A CA 2534664 A1 CA2534664 A1 CA 2534664A1
Authority
CA
Canada
Prior art keywords
modafinil
modulated
modafinil compositions
enantiomerically
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002534664A
Other languages
French (fr)
Other versions
CA2534664C (en
Inventor
Magali Bourghol Hickey
Matthew Peterson
Orn Almarsson
Mark Oliveira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/660,202 external-priority patent/US7927613B2/en
Application filed by Individual filed Critical Individual
Publication of CA2534664A1 publication Critical patent/CA2534664A1/en
Application granted granted Critical
Publication of CA2534664C publication Critical patent/CA2534664C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid

Abstract

Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.

Claims
CA2534664A 2003-09-04 2004-09-04 Modafinil compositions Expired - Fee Related CA2534664C (en)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US32777203A 2003-09-04 2003-09-04
USUS03/27772 2003-09-04
US10/660,202 2003-09-11
US10/660,202 US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions
US50820803P 2003-10-02 2003-10-02
US60/508,208 2003-10-02
US54275204P 2004-02-06 2004-02-06
US60/542,752 2004-02-06
US40628804A 2004-02-26 2004-02-26
USUS04/06288 2004-02-26
US56041104P 2004-04-06 2004-04-06
US60/560,411 2004-04-06
US57341204P 2004-05-21 2004-05-21
US60/573,412 2004-05-21
US57917604P 2004-06-12 2004-06-12
US60/579,176 2004-06-12
US58199204P 2004-06-22 2004-06-22
US60/581,992 2004-06-22
US58675204P 2004-07-09 2004-07-09
US60/586,752 2004-07-09
US58823604P 2004-07-15 2004-07-15
US60/588,236 2004-07-15
PCT/US2004/029013 WO2005023198A2 (en) 2003-09-04 2004-09-04 Modafinil compositions

Publications (2)

Publication Number Publication Date
CA2534664A1 true CA2534664A1 (en) 2005-03-17
CA2534664C CA2534664C (en) 2012-10-30

Family

ID=34280325

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2534664A Expired - Fee Related CA2534664C (en) 2003-09-04 2004-09-04 Modafinil compositions

Country Status (6)

Country Link
KR (1) KR101184797B1 (en)
AU (1) AU2004270238B2 (en)
CA (1) CA2534664C (en)
MX (1) MXPA06002507A (en)
NZ (1) NZ545133A (en)
WO (1) WO2005023198A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
FR2849029B1 (en) 2002-12-20 2005-03-18 Lafon Labor PROCESS FOR THE PREPARATION AND CRYSTALLINE FORMS OF OPTICAL ENANTIOMERS OF MODAFINIL.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2005099822A2 (en) * 2004-04-13 2005-10-27 Cephalon, Inc. Reduction of drug / drug interactions with modafinil
ATE483455T1 (en) * 2004-05-28 2010-10-15 Transform Pharmaceuticals Inc MIXED CRYSTALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2007013962A2 (en) * 2005-07-21 2007-02-01 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
ITMI20051971A1 (en) * 2005-10-18 2007-04-19 Dipharma Spa PROCEDURE FOR THE PREPARATION OF - MODAFINIL
US20070293702A1 (en) * 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US20100130616A1 (en) * 2006-11-09 2010-05-27 Novartis Ag Salt of aliskiren with orotic acid
WO2008075736A1 (en) 2006-12-21 2008-06-26 Astellas Pharma Inc. Method for producing c-glycoside derivative and synthetic intermediate thereof
WO2009025791A2 (en) 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
US8871793B2 (en) * 2009-12-23 2014-10-28 Nuformix Limited Metaxalone cocrystals
KR102372908B1 (en) * 2021-09-27 2022-03-10 유니셀랩 주식회사 Novel co-crystal of pelubiprofen/mandelic acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593809B1 (en) * 1986-01-31 1988-07-22 Lafon Labor BENZHYDRYLSULFINYLACETAMIDE, PROCESS FOR PREPARATION AND THERAPEUTIC USE
US7141555B2 (en) * 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
EP1608339B8 (en) * 2003-02-28 2012-04-25 McNeill-PPC, Inc. Pharmaceutical co-crystal of celecoxib-nicotinamide

Also Published As

Publication number Publication date
CA2534664C (en) 2012-10-30
AU2004270238A1 (en) 2005-03-17
WO2005023198A2 (en) 2005-03-17
KR101184797B1 (en) 2012-09-20
MXPA06002507A (en) 2006-06-20
WO2005023198A3 (en) 2005-07-14
NZ545133A (en) 2009-12-24
AU2004270238B2 (en) 2010-07-29
KR20060128831A (en) 2006-12-14

Similar Documents

Publication Publication Date Title
CA2534664A1 (en) Modafinil compositions
SE0401971D0 (en) Piperidne derivatives
HRP20050262A2 (en) Pyrrolidone derivatives as maob inhibitors
PL356904A1 (en) Pharmaceutical compositions
WO2006132647A3 (en) Antimicrobial copolymers and uses thereof
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
WO2003000226A3 (en) Pharmaceutical compositions containing polymer and drug assemblies
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
BR0209020A (en) Polyallylamine Pharmaceutical Composition
CA2556514A1 (en) Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
SE0402762D0 (en) Indazole sulphonamide derivatives
IS8430A (en) Medicines containing (2R) -2-propyl octanoic acid as the active ingredient
ATE386725T1 (en) HETEROCYCLYL COMPOUNDS
WO2004069146A3 (en) L-dopa amide derivatives and uses thereof
EP2471525A3 (en) Facially amphiphllic polymers and oligomers and uses thereof
DE60142913D1 (en) DRUG SOLUTIONS CONTAIN MODAFINIL COMPOUNDS
WO2003066597A3 (en) Guanidino compounds
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
EP2020233A3 (en) Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
BRPI0413777A (en) modafinil compositions
SE0001916D0 (en) Novel formulation
WO2006044548A3 (en) Clopidogrel compositions

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160906